BioWorld

May 2, 2006

View Archived Issues

CardioKine Brings In $50M Via Series B For Lixivaptan

CardioKine Inc., just 2 years old, is ready to move its lead product, Lixivaptan, into Phase III trials, and it raised $50 million to do so. (BioWorld Today) Read More

NeoPharm Trimming Jobs To Contain Costs Going Forward

Read More

GAO Recommends Improved Post-Approval Drug Oversight

Read More

Vaccinoma Files Australian IPO For Melanoma Vaccine

Read More

Clinic Roundup

Read More

Other News To Note

Read More